China's Vaccine Sector Shows Signs Of Recovery Following Scandals, Popular Boycott
This article was originally published in PharmAsia News
Executive Summary
BEIJING - In a sign that China's vaccine sector is beginning to recover from a series of scandals set in motion by allegations surrounding faulty products, the country's leading vaccine developer, Sinovac Biotech, has received a substantial new order for a hepatitis A defense that the Beijing government will administer to children across the capital